Published in
American Society of Hematology, Blood, 10(129), p. 1380-1388
DOI: 10.1182/blood-2016-09-738385
Links
Tools
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
Journal article published in 2017 by
Reid W. Merryman 
,
Haesook T. Kim,
Pier Luigi Zinzani,
Carmelo Carlo-Stella,
Stephen M. Ansell,
Miguel-Angel Perales,
Abraham Avigdor,
Ahmad S. Halwani,
Roch Houot,
Tony Marchand,
Nathalie Dhedin,
Willy Lescaut,
Anne Thiebaut-Bertrand,
Sylvie François,
Aspasia Stamatoullas-Bastard
and other authors.
,
Haesook T. Kim,
Pier Luigi Zinzani,
Carmelo Carlo-Stella,
Stephen M. Ansell,
Miguel-Angel Perales,
Abraham Avigdor,
Ahmad S. Halwani,
Roch Houot,
Tony Marchand,
Nathalie Dhedin,
Willy Lescaut,
Anne Thiebaut-Bertrand,
Sylvie François,
Aspasia Stamatoullas-Bastard
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points HSCT after PD-1 blockade is feasible, although may be associated with increased early immune toxicity. PD-1 blockade may cause persistent depletion of PD1+ T cells and alterations in T-cell differentiation impacting subsequent treatment.